Promising Inhibitor Combination for Hard-to-treat Leukemia Subtypes Discovered
M. Andrés Blanco, PhD, Assistant Professor, Biomedical Sciences, was one of the researchers on this team.
New Tools for Treating Advanced Retinal Degenerations Developed by Penn Vet Researchers
Researchers at Penn Vet have developed four novel DNA promoters.
Capstan Therapeutics Begins Phase 1 Trial of CAR-T Therapy for Autoimmune Disease
Capstan Therapeutics, a biotechnology company spun out of Penn, has initiated its Phase 1 trial of an in vivo CAR-T therapy.
Penn Vet Collaborates on Mars Study to Evaluate Pets’ Contribution to Human Wellbeing
Pet care business Mars, Inc. launched the Pets and Wellbeing Study (PAWS), a multi-year research program to study the impact of cats and dogs on human mental health.
Penn Vet Uses Augmented Reality to Perform Successful Brain Surgery on a Dog
Geddy became the first dog to undergo successful brain surgery using AR and infrared real-time guided resection.
Vetigenics secures $6 million seed financing
The funding will be used to further advance clinical-stage programs toward pivotal trials, accelerate preclinical candidates, and scale the company's operations and manufacturing.
Penn Vet Announces mRNA Research Initiative for Veterinary Vaccine Science
The University of Pennsylvania School of Veterinary Medicine (Penn Vet) has launched an mRNA Research Initiative to advance the development of veterinary mRNA-based vaccines and therapies.
Scout Bio Acquired by Leading Animal Health Company
French company Ceva Santé Animale announced that it is acquiring Scout Bio.
Long-term Penn Research Across Disciplines Leads to the Development of a New ‘Patch’ that Uses Natural Body Motion to Fix Disc Herniation
A new biologic “patch” that is activated by a person’s natural motion has the potential to fix herniated discs in people’s backs, according to researchers at Penn Medicine and the CMC VA Medical Cente
Vetigenics’ Treats its First Canine Cancer Patient
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.